Endpoints for clinical trials on treatment of hepatitis C

Journal of Hepatology

Volumn 45, Issue 4, 2006, Pages 473-475

  Kang, Hellan ^a   Lok, Anna S F ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIFIBROTIC AGENT; ANTIINFLAMMATORY AGENT; APOPTOSIS INHIBITOR; ENZYME INHIBITOR; GLYCYRRHIZIC ACID; HERBACEOUS AGENT; INTERFERON; PLACEBO; PROTEINASE INHIBITOR; RIBAVIRIN;

ASCITES; BIOASSAY; CLINICAL PROTOCOL; CLINICAL RESEARCH; CLINICAL TRIAL; DRUG TOLERANCE; EDITORIAL; FOLLOW UP; HEPATITIS C; HERBAL MEDICINE; HUMAN; HYPERTENSION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAINTENANCE DRUG DOSE; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUALITY OF LIFE; RISK ASSESSMENT; SUSTAINED VIROLOGICAL RESPONSE; TACHYCARDIA; THROMBOPHLEBITIS; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTIVIRAL AGENTS; CLINICAL TRIALS; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS;

EID: 33748096774     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2006.07.007     Document Type: Editorial

References (23)

1. Bucher H.C., Guyatt G.H., Cook D.J., et al. Users' guides to the medical literature: XIX. Applying clinical trial results. A. How to use an article measuring the effect of an intervention on surrogate endpoints Evidence-Based Medicine Working Group. Jama 282 (1999) 771-778
2. Formann E., Steindl-Munda P., Hofer H., et al. Long-term follow-up of chronic hepatitis C patients with sustained virological response to various forms of interferon-based anti-viral therapy. Aliment Pharmacol Ther 23 (2006) 507-511
3. Veldt B.J., Saracco G., Boyer N., et al. Long-term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy. Gut 53 (2004) 1504-1508
4. Poynard T., McHutchison J., Manns M., et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 122 (2002) 1303-1313
5. Marcellin P., Boyer N., Gervais A., et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med 127 (1997) 875-881
6. Reichard O., Glaumann H., Fryden A., et al. Long-term follow-up of chronic hepatitis C patients with sustained virological response to alpha-interferon. J Hepatol 30 (1999) 783-787
7. Poynard T., Moussalli J., Ratziu V., et al. Effect of interferon therapy on the natural history of hepatitis C virus-related cirrhosis and hepatocellular carcinoma. Clin Liver Dis 3 (1999) 869-881
8. Yoshida H., Shiratori Y., Moriyama M., et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med 131 (1999) 174-181
9. Okanoue T., Minami M., Makiyama A., et al. Natural course of asymptomatic hepatitis C virus-infected patients and hepatocellular carcinoma after interferon therapy. Clin Gastroenterol Hepatol 3 (2005) S89-S91
10. Ikeda K., Saitoh S., Arase Y., et al. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: a long-term observation study of 1643 patients using statistical bias correction with proportional hazard analysis. Hepatology 29 (1999) 1124-1130
11. Heathcote E.J. Prevention of hepatitis C virus-related hepatocellular carcinoma. Gastroenterology 127 (2004) S294-S302
12. Shiratori Y., Ito Y., Yokosuka O., et al. Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival. Ann Intern Med 142 (2005) 105-114
13. Orlent H., Hansen B.E., Willems M., Brouwer J.T., Huber R., Kullak-Ublick G.A., et al. Biochemical and histological effects of 26 weeks of glycyrrhizin treatment in chronic hepatitis C: A randomized phase II trial. J Hepatol 45 (2006) 539-546
14. van Rossum T.G., Vulto A.G., Hop W.C., et al. Glycyrrhizin-induced reduction of ALT in European patients with chronic hepatitis C. Am J Gastroenterol 96 (2001) 2432-2437
15. Ikeda K., Arase Y., Kobayashi M., et al. A long-term glycyrrhizin injection therapy reduces hepatocellular carcinogenesis rate in patients with interferon-resistant active chronic hepatitis C: a cohort study of 1249 patients. Dig Dis Sci 51 (2006) 603-609
16. Pradat P., Alberti A., Poynard T., et al. Predictive value of ALT levels for histologic findings in chronic hepatitis C: a European collaborative study. Hepatology 36 (2002) 973-977
17. Ahmed A., and Keeffe E.B. Chronic hepatitis C with normal aminotransferase levels. Gastroenterology 126 (2004) 1409-1415
18. Hui C.K., Belaye T., Montegrande K., et al. A comparison in the progression of liver fibrosis in chronic hepatitis C between persistently normal and elevated transaminase. J Hepatol 38 (2003) 511-517
19. Ghany M.G., Kleiner D.E., Alter H., et al. Progression of fibrosis in chronic hepatitis C. Gastroenterology 124 (2003) 97-104
20. Shiffman M.L., Diago M., Tran A., et al. Chronic hepatitis C in patients with persistently normal alanine transaminase levels. Clin Gastroenterol Hepatol 4 (2006) 645-652
21. Prati D., Taioli E., Zanella A., et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 137 (2002) 1-10
22. Zeuzem S., Diago M., Gane E., et al. Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology 127 (2004) 1724-1732
23. Rodger A.J., Jolley D., Thompson S.C., et al. The impact of diagnosis of hepatitis C virus on quality of life. Hepatology 30 (1999) 1299-1301